Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
- Sponsor
- University of California, Irvine
- Study ID
- NCT00667472
- Phase
- PHASE1
- Status
- Withdrawn
Conditions
- Port-Wine Stain
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGCombined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
- Pulsed Dye Laser — DEVICECombined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Study Details
The purpose of this study is to improve port wine stain therapeutic outcome in response to laser therapy. The researcher want to determine whether the combined use of pulsed dye laser therapy and topical ranibizumab will improve port wine stain therapeutic outcome.
Key Dates
- First listed
- Apr 28, 2008
- Start date
- Mar 31, 2008
- Status verified
- Oct 2022
- Primary completion
- Nov 30, 2013
- Completion
- Nov 30, 2013
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: RanibizumabCombined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
- Experimental: Pulsed Dye LaserCombined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Primary Outcome Measure
Port Wine Stain response to laser treatment [ Time Frame: 8 weeks ]
Related Studies
- A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDTPHASE2 · Recruiting · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Irvine, California
- Tolerability of 532 nm Laser Treatment of Port Wine StainsRecruiting · Massachusetts General Hospital · Boston, Massachusetts